Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Korsana Biosciences's price to book ratio was 8.5× on Jan 31, 2025, against 4.0× a year earlier. Over the last 5 years it ranged from 2.9× to 20.1×, with a median of 9.1×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Jan 31, 2025 | 8.5× | +1.5 |
| 2024 | Dec 31, 2024 | 7.0× | +2.5 |
| 2023 | Dec 29, 2023 | 4.5× | −7.6 |
| 2022 | Dec 30, 2022 | 12.1× | +2.8 |
| 2021 | Dec 31, 2021 | 9.2× | −0.4 |
| 2020 | Dec 31, 2020 | 9.7× | +5.3 |
| 2019 | Dec 31, 2019 | 4.4× | – |
See a number that looks wrong?